【摘要】 目的探讨急性肾盂肾炎致病菌的临床分析及药物疗效。方法 2009年2月~2014年4月选择在我院诊治的急性肾盂肾炎患者80例,根据随机抽签原则分为哌拉西林/他唑巴坦治疗组与头孢地嗪治疗组各40例,头孢地嗪治疗组选择头孢地嗪治疗,哌拉西林/他唑巴坦治疗组选择注射用哌拉西林/他唑巴坦治疗。结果果哌拉西林/他唑巴坦治疗组的治愈率为95.0%,头孢地嗪治疗组治愈率为80.0%,哌拉西林/他唑巴坦治疗组的治愈率明显高于头孢地嗪治疗组(P<0.05)。两组患者治疗期间都无严重并发症发生,随访至今,未见局部复发。结论急性肾盂肾炎的致病菌多为大肠杆菌,哌拉西林/他唑巴坦的应用治疗能提高治愈率,安全性好,值得推广应用。更多还原

【Abstract】 Objective To explore the clinical and drug therapeutic effect of acute pyelonephritis pathogenic bacteria. Methods From February 2009 to April 2014, 80 cases of acute pyelonephritis pathogenic in our hospital were randomly divided into Piperacillin/Tazobactam group and Cefodizime group, with 40 cases. Cefodizime group was given cefodizime, and Piperacillin/Tazobactam group was given Piperacillin/Tazobactam. Results The recovery rate of Piperacillin/Tazobactam group was 95.0%, significantly higher than Cefodizime group(80.0%)(P<0.05). Of the two groups, there were serious complications occurred during the treatment and no local recurrence during following up. Conclusions The E. coli bacteria is the key pathogenic bacterium, Piperacillin/Tazobactam application effectively improved the recovery rate, worth promotion.更多还原